West Nile virus (WNV) mainly infects birds, horses and humans. Outcomes of the infection range from light uncharacteristic signs to fatal neurologic disease. The main objectives of the present study were to measure serum IgG and IgM antibodies in naturally exposed and vaccinated horses and to compare results of hemagglutination-inhibition test (HIT), enzymelinked immunosorbent assay (ELISA) and plaque reduction neutralization test (PRNT).
Introduction

West Nile virus (WNV) is a mosquito-borne zoonotic arbovirus belonging to the genus
Flavivirus in the family Flaviviridae (Smithburn et al., 1940) . It is transmitted in natural cycles between mosquitoes, (mainly the genus Culex), and wild birds (Bakonyi et Antibodies can be identified in equine serum by IgM capture enzyme-linked immunosorbent assay (ELISA), haemagglutination inhibition test (HIT), IgG ELISA, plaque reduction neutralisation test (PRNT), and microtitre virus neutralisation (VN) (Beaty et al., 1989; Hayes, 1989) . Virus-neutralizing antibody responses persist for longer than WNV-specific IgM levels in serum. The duration of IgM appears to be short-lived in horses; hence it is useful for identifying and differentiating recent infections from previously exposed animals.
Horses infected with either WNV lineage 1 or lineage 2 elicit a similar antibody profile in serum samples and there is not any notable differences in the antibody profile (CastilloOlivares et al., 2011).
The emergence of lineage 2 strains of WNV in Europe as a cause of clinical disease and mortality in horses raised the question whether the existing WNV vaccines -which are all based on lineage 1 strains -protect against circulating lineage 2 strains of WNV. Up until now the lineage 1 vaccines turned out to be effective in protecting against lineage 2 strains of the disease as well (Minke et al., 2011) .
The main objectives of the present study were to measure serum IgG and IgM antibodies in naturally exposed and vaccinated horses and to compare results of HIT, competitive ELISA and PRNT.
Materials and methods
Altogether we examined 224 horses for the presence of WNV antibodies. Two different examinations were performed (Table 1. ). In the first examination after collecting a primary sera sample for WNV antibodies 182 animals were vaccinated with an inactivated virus vaccine according to the user's manual of the product (Duvaxyn® WNV, Pfizer, in the EU now Equip® WNV, Zoetis; in the US WEST NILE-INNOVATOR®, Zoetis). Out of th182 horses 105 animals were naturally exposed and 77 had been vaccinated before. Naturally At the time of the sera sample collection there were no ELISA or capture ELISA kits available in Hungary, so on the first occasion our samples were tested by the National Centre for Epidemiology, where IgG levels were measured with HIT validated for human screening.
The HIT was performed as described by Clarke and Casals, with a microtitre-plate format.
We briefly summarize the key steps of the method. Nonspecific inhibitors and natural hemagglutinins were removed by kaolin adsorption. Dilutions of kaolin treated equine serum were mixed with 8 hemagglutination (HA) units of suckling mouse WNV antigen and incubated at 4°C overnight. Goose erythrocytes were then added to the mixture, and the solution was incubated for an additional hour at room temperature (Clarke and Casals, 1958 ).
The HIT titre was determined as the highest dilution of equine serum that caused complete During the second examination, 42 out of the 224 cases were evaluated for seroprevalence no further tests were carried out. The selection of this group of 42 horses was restricted to areas of the country where previously WNV disease was detected since our intention was to look for subclinical seroconversion rates by measuring the IgG titer with HIT. 
I examination
HIT
Before presenting our results, we call the attention of the reader to averages shown in our tables and figures were calculated on a logarithmic scale. The rationale behind this method was to avoid a few extremely high (1:5120 and higher) values heavily altering our results.
Since one cannot assign any biological significance to these outstanding values (i.e., we cannot assume that a horse with 1:10240 IgG titer is better protected against the disease than one with 1:5120 IgG titer), reducing their effect on the averages by moving to the logarithmic scale seemed a more relevant approach. By the same argument one can conclude that the averages themselves, regardless of the method they were calculated with, contain little information about the studied groups. To remedy this we will provide some additional descriptive statistics. 
ELISA/PRNT/ HIT
Altogether 90 sera samples were examined for IgG levels, which we obtained from the 41 horses as shown in Table 6 . 
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We calculated sensitivity and specificity values for both HIT and ELISA taking PRNT results
as reference values (These are just the positive/negative percent agreements from the above contingency tables) Sensitivity was 82% and specificity was 92% for HIT, while sensitivity was 95% and specificity was 92% for ELISA (Table 9) .
Comparison Sensitivity Specificity
PRNT / HIT 63/(63+14) = 82% 12/(12+1) = 92%
PRNT / ELISA 73/(73+4) = 95% 12/(12+1) = 92% Table 9 : Sensitivity and specificity values
Only the post vaccination samples were tested for IgM with Capture ELISA. We detected 13
IgM positive samples.
II examination
42 of the horses were not participating in the vaccination program, in these cases we investigated if the horses had seroconversion due to natural infection.
40 of the horses examined previously shared a stall with confirmed cases of neuroinvasive WNV infection. 27 horses out of the 40 were seronegative and 13 were seronegative.
Two of the 42 horses were survivors of neuroinvasive WNV, both confirmed by high IgG and IgM levels at the acute phase of the disease. One of these two cases was shown no humoral protection against WNV 3 years after infection; the other horse had sufficient level of IgG (1:160), 1 year after infection, to be able to prevent a re-infection.
Discussion
The sera sampling prior to vaccination was performed in March, when there was a negligible chance of a recent infection, due to the seasonal nature of the disease (Smithburn et al., 1940) . Consequently, vaccination which induces a protection during the whole year would be beneficial. Since it was verified by all three serological methods in this study that some horses lose protective level of antibody in less than 12 months after the primary vaccination, we
suggest that the first booster should be applied sooner.
Comparing the post vaccination titres we found that the IgG average levels of groups A and B and groups C and D did not significantly diverge. Taking a closer look at the actual distribution of the values within the groups, we found that data from groups C and D showed a more homogeneous profile; hence the post-vaccination IgG levels in these groups were more reliably in the high domain than those of the horses vaccinated for the first time in the year of the study.
We do not have accurate knowledge of how the IgG levels predict the length of the immunity;
however our results suggest a hypothesis, that one should expect the presence of antibodies to persist if the initial IgG level is sufficiently high. Naturally to make such a hypothesis quantitative and to confirm it one would need to conduct a longitudinal study.
Hemagglutination is a general property of the arbovirus group where WNV also belongs. (Sabin, 1951) The descriptive statistics indicate that the HIT is less sensitive than the ELISA and PRNT. However it is worth noting that out of the 14 cases where the PRNT result was positive and the HIT result was negative, 11 cases gave border PRNT results. According to these results HIT is not a sufficient method to detect slightly elevated, border positive antibody titres.
Some strains of a given virus may show greater capacity than others to yield an HA antigen (Clarke and Casals, 1958) . Based on this, sensitivity of the HIT does not only depend on the test itself but also on the WNV strain.
All members of the genus Flavivirus share antigenic epitopes, as revealed by cross-reactivity in the HIT (Casals et al., 1954) . Therefore, commercially available plates, not necessarily coated with homologous antigen, can be used for antibody detection in serum by ELISA. Both HIT and ELISA should be followed by a neutralization assay to complete identification within that the presence of IgM is not indicating natural WNV infections, as it has been already reported in a previous study (Jonquiere, 2010) .
In the second examination we tested for seroconversion due to natural infection, on 40 cases, which previously shared a stall with confirmed cases of neuroinvasive WNV infection. 32.5
% of the studied cases were seropositive. This is a higher value compared to our findings in the first examination's naturally exposed cases (25.71%), but according to statistical analysis (two sample z-test, 0.9 confidence level) the difference between the two measured value is not significant. Based on this it is not possible to rule out that horses coming from environments where infected horses were detected are not more exposed to the disease, but to confirm or reject this statement a larger sample would be needed. 
Conclusions
The ratio of seropositive horses is high in Hungary. There were cases where protective antibodies could not be measured in 12 months after primary vaccination; therefore we suggest that the first booster should be repeated earlier than a year after. Flavivirus infected sera show cross-reactions in serodiagnosis with heterologous flavivirus infections. Therefore PRNT is still used as the reference assay for specific diagnosis of WNV infection. ELISA has the advantage of being a faster and less expensive alternative which is more accessible for everyday use. HIT is not suitable for diagnostics; however it was a useful tool in this study to gain statistical information about the tendencies within a fixed population of horses. Based on our findings it was not possible to differentiate infected horses from recently vaccinated horses using the MAC-ELISA. Following neuroinvasive infections there is no available data about the duration of protective humural or cellular immunity.
